Methylpiperazine

Methylpiperazine

SCHEMBL4771183

CN1CCN(C(=O)c2ccc(-c3cc4c(Nc5cccc(Cl)c5)ncnc4[nH]3)cc2)CC1.CN1CCNCC1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.49
BTK Q06187 4/20 0.49
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
MKNK2 Q9HBH9 2/20 0.46
BRAF P15056 4/20 0.46
TNNI3K Q59H18 4/20 0.46
WDR5 P61964 1/20 0.44
KMT2A Q03164 1/20 0.44
TBK1 Q9UHD2 2/20 0.44
KIT P10721 2/20 0.43
MAPKAPK2 P49137 1/20 0.42
AURKB Q96GD4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769173 0.96 RIPK1 (0.53) RIPK1BTKABL1BCRBRAF
SCHEMBL4773340 0.86 NPC1 (0.53) RIPK1BTKABL1BCRBRAF
SCHEMBL4352904 0.82 TTBK1 (0.51) ABL1BRAFTNNI3K
SCHEMBL20139009 0.80 EGFR (0.54) RIPK1BTKMKNK2BRAFTNNI3K
SCHEMBL4065929 0.80 RIPK1 (0.60) RIPK1BTKWDR5KMT2ATBK1
SCHEMBL7492081 0.80 EGFR (0.58) ABL1BRAFTNNI3K
SCHEMBL4766930 0.80 KDR (0.54) BTKABL1BCRBRAFTNNI3K
SCHEMBL7497707 0.79 BRAF (0.54) ABL1BRAFTNNI3KKMT2A
Hydrochloric Acid SCHEMBL4764268 0.79 KDR (0.54) BTKABL1BCRBRAFTNNI3K
SCHEMBL13604150 0.79 RIPK1 (0.61) RIPK1BTKWDR5KMT2ATBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
US-6180636-B1 USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-01-30 US disclosed
EP-0938486-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-09-01 EP disclosed
WO-1998007726-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1998-02-26 WO disclosed